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Introduction
Respiratory diseases are an important cause of morbidity
in young children.1 The prevalence of asthma and
persistent wheeze in children aged 1–4 years is between
10% and 20%,2,3 the variation apparently the result of
differing definitions. National and international
consensus reports recommend sodium cromoglycate as
prophylactic agent of first choice in young children with
moderate asthma.4,5
Sodium cromoglycate is a safe prophylactic drug that
is widely used to treat asthma in children, although its
mechanism of action is not fully understood.6,7 Despite
widespread use, the effect of inhaled sodium
cromoglycate in very young children with moderate
asthma has hardly been studied. Several placebo-
controlled trials8–18 have been reported but most were
hospital-based, studied patients with severe asthma, had
follow-up periods shorter than 10 weeks, and studied
medication inhaled by nebulisation. Six of these studies
showed improvement of symptoms in comparison with
placebo,8–13 but in five sodium cromoglycate was no
better than placebo.14–18
Data on the prescription of antiasthma drugs in
primary and secondary care show a trend of decreasing
use of sodium cromoglycate and increasing use of
inhaled steroids.19 Because there is no convincing
evidence that inhaled steroids, even in daily doses of less
than 400 mg, are without side-effects in the long-term
treatment of young children, there is still a potential role
for sodium cromoglycate for treating moderate
asthma.20,21 König and Shaffer22 suggested in 1996 (based
on a retrospective study) that treatment with sodium
cromoglycate improves the long-term prognosis of
childhood asthma.
Nebulisation in young children is tedious and time-
consuming and therefore used mainly in severe asthma.
The availability of spacer devices with face-masks has
extended the use of metered-dose inhalers to children of
preschool age. In the Netherlands most children with
moderate asthma are treated by general practitioners
(GPs). Little is known, however, about the feasibility of
and compliance with long-term prophylactic therapy
when medication is inhaled through a spacer device and
face-mask at home in young children with moderate
asthma. We undertook a study to investigate these issues
in a comparison of inhaled sodium cromoglycate and
placebo.
Methods
Children aged 1–4 years who had previously been on
medication specifically prescribed for respiratory problems (oral
or inhaled bronchodilators, oral or inhaled steroids, sodium
cromoglycate or nedocromil sodium [though the latter is rarely
used in young children], ketotifen, deptropine) were selected
from the computer files of 151 GPs in the Rotterdam area. On
Summary
Background Inhalation therapy with sodium cromoglycate
is recommended as the first-line prophylactic treatment
for moderate asthma in children. The availability of spacer
devices with face-masks has extended the applicability of
metered-dose inhalers to younger children. We studied the
feasibility and effects of this therapy compared with
placebo in children aged 1–4 years.
Methods 218 children aged 1–4 years with moderate
asthma were recruited through 151 general practitioners
between March, 1995, and March, 1996. They were
randomly assigned sodium cromoglycate (10 mg three
times daily) or placebo, given by inhaler with spacer
device and face-mask for 5 months. Rescue medication
(ipratropium plus fenoterol aerosol) was available during
the baseline period of 1 month and the intervention
period. Parents completed a daily symptom-score list. The
primary outcome measure was the proportion of symptom-
free days in months 2 to 5. Analysis was by both intention
to treat and on treatment.
Findings 167 (77%) children completed the trial. 131
(78%) of these children used at least 80% of the
recommended dose. Of the 51 children who stopped
prematurely, 23 had difficulties with inhaled treatment.
The mean proportion of symptom-free days for both groups
was greater for the treatment period than for the baseline
period (95% CI for mean difference 5·1 to 17·5
cromoglycate, 11·9 to 23·3 placebo). However there were
no differences between the sodium cromoglycate and
placebo groups in the proportion of symptom-free days
(mean 65·7 [SD 25·3] vs 64·3 [24·5]%; 95% CI for
difference 28·46 to 5·70) or in any other outcome
measure.
Interpretation Our study in a general practice setting
shows that inhalation therapy with a spacer device and
face-mask is feasible in a majority of children below the
age of 4 years. However, long-term prophylactic therapy
with inhaled sodium cromoglycate is not more effective
than placebo in this age-group.
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behalf of the GP, we sent a postal questionnaire to each child’s
parents, enquiring about the child’s symptoms and current anti-
asthma medication. We defined moderate asthma as one or
more of: more than 12 episodes of coughing, wheeze, or
dyspnoea during the past year; use of antiasthma medication;
and at least two of the following three during the past month—
coughing, wheezing, or dyspnoea more than once a week;
interference of respiratory symptoms with daily activities; and
interference of symptoms with sleep. Children who had been
prescribed oral or inhaled steroids or who had been admitted to
hospital for acute asthma in the past were classified as having
severe asthma. With the GP’s approval, the parents of each
child classified as having moderate asthma were asked to join
the study. Exclusion criteria were congenital disorders and
language difficulties (inability to speak Dutch adequately).
Children were enrolled from March, 1995, to March, 1996,
to make sure the trial period included all four seasons. During
the first visit, the research physician recorded the child’s
medical history and condition at that time, examined the
respiratory tract, ears, nose, and throat, and measured height
and weight. The parents gave written informed consent.
Enrolled children entered a baseline period of 4 weeks,
during which only rescue medication (ipratropium plus
fenoterol aerosol; Berodual, Boehringer Ingelheim, Germany)
was available. If the child was already using prophylactic
medication, the baseline period was preceded by a washout
period of 3 weeks.
At the end of the baseline period, the children were randomly
assigned inhalation therapy with either sodium cromoglycate or
placebo, 10 mg (two puffs) three times daily with a spacer
device and face-mask (Aerochamber, Boehringer Ingelheim).
Study medication (sodium cromoglycate and placebo) was
prepared by Fisons plc, Loughborough, UK. We randomised in
blocks of six patients and stratified for age, assigning blocks by
years of age (1, 2, and 3 years). Parents were provided with
rescue medication to be used in case of exacerbation. The study
medication was given for 5 months.
For use of the inhaler, parents were instructed to shake the
cannister and spray it into the spacer twice, with an interval of
5 s, fitting the facemask tightly around the child’s nose and
mouth as from the first actuation, and to have the child breathe
normally for 30 s. We instructed the parents to rinse the spacer
device with tap water and allow it to drain, no more than once a
week.
During the trial, each child was visited at home once a month
by a research nurse. During the visit the nurse checked the
inhalation technique with the parents, and asked about
respiratory or other symptoms, side-effects, difficulties with the
spacer device, and visits to the GP or other clinician.
Throughout the study, treatment allocation was concealed from
parents, patients, GPs, the research physician, and nurses.
Since there is no suitable method of measuring lung function
in this age-group at home, symptoms are the most relevant
measure of the effect of treatment.23 We asked parents to fill in a
daily symptom-score list (panel) to record their child’s asthma
symptoms, limitation of activity during the day and at night,
and use of trial and rescue medication.
The primary outcome measure was the proportion of
symptom-free days in months 2–5 of the intervention period.
Other outcome measures were number of symptoms (possible
scores 0–4 per day), use of rescue medication, loss of
participants during the trial, need for additional medication,
need for GP visits, referrals to secondary care, and parent’s
guess about the type of treatment. We asked parents of children
withdrawn during the trial to continue filling in the daily
symptom-score list for the remainder of the trial period.
All GPs were advised to prescribe a short course of oral
prednisone if asthma symptoms could not be controlled by trial
or rescue medication. Reasons for withdrawal from the trial
were: more than one exacerbation that had to be treated with
oral prednisone; prescription of long-term therapy with inhaled
steroids; and hospital admission for exacerbation,
adenoidectomy, or tonsillectomy.
At the beginning of the trial we weighed a random sample of
full cannisters of study medication. After the trial all cannisters
were weighed on the same balance (Mettler AE 260 deltarange,
Tiel, Netherlands) to assess compliance.
A pilot study showed that children with moderate asthma had
on average 1 symptom-free day in 2, as in a study by Cogswell
and colleagues.9 To detect a difference in proportion of
symptom-free days between cromoglycate and placebo of 20%
at a significance level of 0·05 and a power of 80%, assuming an
SD of 32%, as calculated from baseline symptom scores, 40
children per group would be needed. We decided to enrol more
children to enable the analysis of subgroups.
The strategy for data analysis was written before the
randomisation code was broken. Analyses were done by both
intention to treat and on treatment. We analysed the main
efficacy variable—ie, proportion of symptom-free days—by a
repeated-measures analysis of covariance. This model involved
both the mean response over the treatment period (to detect a
possible treatment effect) and a linear trend (to detect a possible
treatment by time interaction) of dependent variables.
Independent variables were test medication (cromoglycate,
Questions for daily symptom-score list
Did you notice your child coughing or
wheezing last night? Yes/no
Was your child awake because of
coughing or wheezing last night? Yes/no
Did you notice coughing, wheezing,
or shortness of breath today? Yes/no
Did these airway symptoms interfere
with the activities of your child? Yes/no
How often did your child inhale trial
medication today? 0/1/2/3 times
How often did your child inhale
Berodual today? 0/1/2/3 or more times
999 did not reply
1303 did not meet
eligibility criteria
104 excluded
86 completed trial81 completed trial
217 did not start
14 withdrawn
28	 withdrawn
15	 inhalation not feasible
3	 not motivated
3	 ENT procedure
5	 exacerbation asthma
2	 side effects
23	 withdrawn
8	 inhalation not feasible
4	 not motivated
1	 ENT procedure
3	 exacerbation eczema
2	 side effects
Questionnaire sent to 2855 children
1856 responded
553 met criteria for moderate asthma
449 invited to take part
232 started trial
109 assigned cromoglycate 109 assigned placebo
218 entered
randomisation
Figure 1: Trial profile
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placebo); sex; seasonal influence (autumn+winter/spring+
summer); and smoking by parents; food allergy; eczema;
experience with inhalation therapy; and positive family history
(all no/yes). Age (months) and baseline value of percentage
symptom-free days were used as covariates. Because of a possible
violation of the normality assumption, we did the same analysis
on arcsinsquare-root-transformed outcome data.24 Separate
analyses of subgroups were done for sex, age, and season.
Differences in side-effects and secondary effect measures were
tested by x2 test, t test, or Fisher’s exact test (two-sided).
The Medical Ethics Committee of Erasmus University
Rotterdam/Academic Hospital Rotterdam approved the trial.
Results
2855 children who had previously been on specific
respiratory medication were selected from 151 general
practices (figure 1). The overall response rate to the
questionnaire was 65%. Respondents and non-
respondents were similar in terms of age and medication
prescribed. 553 children (30% of respondents) met our
inclusion criteria for moderate asthma. 104 were not
invited to take part, because the GP did not approve of
inclusion (mostly because of social circumstances, 20),
because we could not contact the parents (43), or
because of congenital disorders (three), language
difficulties (11), corticosteroid therapy (21), or an
adenoidectomy/tonsillectomy planned in the near future
(six). 449 children were invited to take part.
Between March, 1995, and March, 1996, 232 children
(42% of those with moderate asthma) entered the
baseline period or washout period. 217 children did not
start the trial; the parents of 72 children refused to
participate because they expected feasibility problems,
109 did not want changes in therapy, 27 did not want
any research, and nine refused for unknown reasons. A
further 14 children were withdrawn during the washout
or baseline period because the inhalation procedure was
not feasible (three), the child had an exacerbation of
asthma (five), an ear, nose, and throat procedure was
planned (two), or other reasons (four). 218 children
remained, of whom 109 were assigned sodium
cromoglycate and 109 placebo.
The groups were similar except for baseline symptom
score (table 1). During the trial period 51 children (23%;
28 in cromoglycate group, 23 in placebo group) were
withdrawn (figure 1). 23 (37%) of the 1-year-olds left
the trial prematurely, compared with 11 (16%) 2-year-
olds, and 17 (19%) 3-year-olds. The main reason for
withdrawal of 1-year-olds was the difficulty parents and
children experienced in using the spacer device. Of the
children who stopped prematurely, the parents of 38 (23
sodium cromoglycate group, 15 placebo group) kept
recording symptoms, although 14 of them registered the
daily symptoms for only part of the remainder of the trial
period. 13 children (five sodium cromoglycate group,
eight placebo group) were lost to follow-up. 167 (77%)
children completed the trial.
Parents of 40 (37%) children in the cromoglycate
group and 33 (30%) children in the placebo group
reported side-effects (table 2). No serious side-effects
were reported for either group by parents or GPs.
Eczema around the place where the mask was applied
occurred in five children in the cromoglycate group and
none in the placebo group (p=0·052). Nine children in
the cromoglycate group and one in the placebo group
had coughing after inhalation (p=0·02). The frequencies
of other side-effects were similar in the two groups.
We estimated compliance from the weights of the
returned cannisters (mean for cromoglycate group 310
[SE 4] g, placebo group 311 [4] g). Of the children who
completed the trial, 66 (81%) in the cromoglycate group
and 65 (76%) in the placebo group used more than 80%
of the recommended dose (p=0·35).
Averaged over months 2–5, the proportion of
symptom-free days in the cromoglycate group was 65·7%
(SD 25·3), compared with 64·3% (24·5) in the placebo
group (95% CI for difference, placebo minus
cromoglycate, 28·46 to 5·70). In both groups of
children, the proportion of symptom-free days improved
significantly during treatment (paired t test, p<0·01;
95% CI, treatment minus baseline, cromoglycate 5·1 to
17·5, placebo 11·9 to 23·3). There was no significant
difference in this increase between the groups (figure 2).
The 95% CI for the difference between placebo and
sodium cromoglycate (percentage symptom-free days)
adjusted for baseline value was 24·6 to 7·7. Analysis of
covariance revealed no significant treatment effect,
significant treatment by time interaction, or influence of
age, sex, eczema, familiarity with inhalation therapy,
seasonal influence, or parental smoking on the overall
proportion of symptom-free days. Baseline values were
predictive of outcome. Analysis of the transformed data
Cromoglycate Placebo
(n=109) (n=109)
Mean (SD) age in years 2·6 (0·9) 2·5 (0·8)
Number aged at entry
12–23 months 34 (31%) 31 (28%)
24–35 months 32 (29%) 36 (33%)
26–48 months 43 (39%) 42 (39%)
Male/female 58/51 64/45
Medical history
Mean (SD)% symptom-free days during 56·5 (31·3) 47·6 (33·2)
baseline period
Perceived influence of season 60 (55%) 57 (52%)
Eczema 61 (56%) 63 (58%)
Food allergy 48 (44%) 47 (43%)
Asthma also induced by exercise 36 (33%) 36 (33%)
Experience with inhalation therapy 40 (37%) 36 (33%)
Family history of asthma 72 (66%) 58 (53%)
Family characteristics
Parental smoking 73 (67%) 58 (53%)
Mean (SD) age mother on day of birth 28·7 (4·5) 28·7 (4·1)
Of non-Dutch origin 5 (5%) 9 (8%)
In day care 43 (39%) 49 (45%)
Mean (SD) position in birth order 1·85 (0·89) 1·94 (0·83)
Education mother low* 66 (61%) 71 (65%)
Education father low* 44 (40%) 41 (38%)
Anthropometry
Mean (SD) length (cm) 93 (9) 93 (8)
Mean (SD) weight (kg) 15·9 (3·1) 15·5 (2·7)
*¶4 years after primary school.
Table 1: Characteristics of treatment groups at start of trial
Cromoglycate Placebo
(n=109) (n=109)
No side-effects 69 (63%) 73 (67%)
Behaviour
More active 6 (6%) 12 (11%)
More sleepy 8 (7%) 5 (5%)
Skin
Eczema around nose and mouth 5 (5%) 0
Other 7 (6%) 8 (7%)
Cough after inhalation 9 (8%) 1 (1%)
Gastrointestinal 5 (5%) 6 (6%)
Other 5 (5%) 4 (4%)
Table 2: Side-effects
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(six vs one), and ketotifen (three vs one).
Growth, both linear and in weight, was similar in the
two treatment groups during the trial.
29% of parents of children in the cromoglycate group
guessed the treatment correctly, whereas 37% of them
thought their child had received placebo. In the placebo
group, 30% of parents guessed the type of treatment
correctly, and 33% thought their child had received
cromoglycate. The remaining parents did not know.
Discussion
This study of long-term prophylactic inhalation therapy
with a spacer device and face mask in 1–4-year-old
children with moderate asthma showed that the
treatment is feasible at home for such children—77% of
the children in our trial used an inhaler for 5 months,
and 78% of users took at least 80% of the recommended
dose. Of those who stopped prematurely, 45% had
difficulty in using the inhaler, particularly the 1-year-
olds. There were no differences in feasibility and
compliance between the treatment groups. By contrast,
Gibson and colleagues25 reported poor compliance in a
2-month observational study in young children attending
a paediatric respiratory clinic. In a study to assess
compliance among adults receiving regular pulmonary
medication in a general-practice setting,26 Dekker and
colleagues could classify only 30% of the patients as
compliant. We think that our better results could be
explained by a selection bias of motivated parents and
the intensive monitoring by the research nurses.
Both groups improved significantly in the proportion
of symptom-free days. This finding can be explained by
the placebo effect and the personal supervision
associated with a clinical trial, as found previously in
many trials on asthma in children.
The two groups did not differ in proportion of
symptom-free days. We could not identify subgroups of
children whose response to cromoglycate was influenced
by age, sex, positive family history, atopic history,
season, or smoking habits of the parents. Geller-
Bernstein and Levin11 found an effect of cromoglycate in
children aged 12 months and older, whereas no effect
was seen in children below this age.
Notable side-effects of inhalation of sodium
cromoglycate were cough directly after inhalation and
eczema around the mouth. The first is well known, the
latter was found previously in one of 29 children.15
The lack of benefit from treatment with sodium
cromoglycate in this trial may have resulted from the
spacer device we used. Several studies have shown
a higher retainment of medication in this than in
other spacer devices,27–29 so perhaps the dose of
sodium cromoglycate reaching the lungs was inadequate
in our trial. On the other hand, other studies have
shown satisfactory drug delivery with this device in
children.30,31
There are few published data on assessment and
monitoring of early childhood asthma, probably because
wheezing disorders in young children are ill-defined. The
limiting factor is our ability to measure the disorder
itself. Most clinical measurement schemes are based on
symptom assessment, even though symptoms are non-
specific and poorly defined, and scoring systems have not
been adequately evaluated.32 However, since symptoms
are directly related to the burden of disease, we question
whether other, more objective, measures of morbidity
gave similar results. On-treatment analysis was done by
repeating the tests only with children who had used more
than 80% of the prescribed medication (66 cromoglycate
group, 65 placebo group). We could not find any
significant differences in outcome (95% CI of difference
between placebo and cromoglycate 28·21 to 6·41).
The number of symptoms per day and use of rescue
medication per month showed no significant differences
between the treatment groups (figure 2). During the
trial, parents of children in the cromoglycate group
reported 368 episodes of illness, often with respiratory
symptoms (164 episodes in 83 children). Parents of
children in the placebo group reported 362 episodes of
illness, 181 (50%) with respiratory symptoms (88
children). 35 children in the cromoglycate group were
taken to their GPs about asthma (61 visits) compared
with 47 children (85 visits) in the placebo group
(p=0·14). Additional medication was used in 29 and 35
children in the cromoglycate and placebo groups,
respectively: antibiotics (13 vs 21), oral steroids (eight in
each group), inhaled steroids (three vs five), deptropine
(five vs six), promethazine (three vs seven), salbutamol
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Figure 2: Mean (SE) proportion of symptom-free
days, number of symptoms per day, and use of
rescue medication
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would be superior.
We do not think the group size limits our conclusions.
We can infer from the 95% CI that the difference
between sodium cromoglycate and placebo, if any, is of
no clinical importance.
We conclude, therefore, that inhalation therapy three
times daily with a spacer device in young children with
moderate asthma is feasible, but that treatment with
sodium cromoglycate via the Aerochamber is no more
effective than placebo. We could not show any benefit of
sodium cromoglycate treatment that balances the effort
and cost of this therapy. Therefore we support the
intentions of national and international guidelines
committees to withdraw the recommendation of sodium
cromoglycate as the first choice in first-line inhaled
prophylactic asthma treatment.33
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